It is time to talk about Alzheimer’s…

Share On Facebook
share on Linkedin

According to WHO currently more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. It is forecasted that as the population ages, the number of people living with dementia will approach 150 million in thirty years. Now there are medications that can alleviate the course of the disease, but there are none that could completely cure patients.


Hence, it is not difficult to assume that a company that finds a cure for a terrible disease will win a real jackpot. Caring for people with Alzheimer’s is expected to cost the American society $20 trillion over the next 40 years, including $15 trillion in Medicare and Medicaid. If a drug is developed to help fight the disease, then everyone wins.

In this context it shouldn’t be a surprise that pharmaceuticals giants like AC Immune, Cassava Sciences, Biogen, Eli Lilly, Mission and AbbVie are pouring billions of dollars into Alzheimer’s research and the development of drugs to treat the disease. By the way, more recently, the Swiss biopharmaceutical company AC Immune announced that a drug it is developing for the treatment of Alzheimer’s disease shows a statistically significant result in slowing down the deterioration of cognitive abilities in subjects. Against this background, the company’s shares first soared above $11, but after a few days they returned to their previous values. The reason for this roller coaster can be attributed to the fact that the actual performance of the drug was not so encouraging.

In the case of Cassava Sciences, Inc. (SAVA) things are also not doing well. The company’s shares came under pressure after the US Food and Drug Administration (FDA) issued a statement from the former lawyer of the US Securities and Exchange Commission (SEC) Jordan Thomas. Long story short, he expressed concerns about the quality of the studies carried out on the drug for Alzheimer’s disease – simufilam – and also called for the termination of clinical trials.

But Biogen still has momentum – its drug is set to be used by more than 300 American medical institutions and is already being administered to some patients. The problem is that the FDA recently called for a federal investigation into the approval of Biogen’s Aduhelm drug for Alzheimer’s. Finally, Eli Lilly also plans to seek US approval of its experimental drug for Alzheimer’s disease by the end of the year.


CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

Do you want to write for our Newspaper? Get in touch:

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211130 16:33:22